Dogs of the Dow Are 2022's Best in Show
All portfolio doctors should prescribe high dividends to remedy rising interest rates and stiff inflation.
In 2022, the first year in recent memory pockmarked by those twin afflictions, dividend-heavy stocks such as , pharmaceuticals, pipelines and many consumer-oriented blue chips like those found in the have held up fine. There is a massive disparity of results within this year's stock,
